Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results - Wikidata - wikimedia - TriplyDB

Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results

Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results

http://www.wikidata.org/entity/Q33397922

about

A Canadian national expert consensus on neoadjuvant therapy for breast cancer: linking practice to evidence and beyond Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future.Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer Surgical treatment of primary breast cancer in the neoadjuvant setting.Quality of reporting of chemotherapy compliance in randomized controlled trials of breast cancer treatment.Neoadjuvant treatment of breast cancer.Gene expression and pathologic response to neoadjuvant chemotherapy in breast cancer.

P2860

Q35239617-3D3105A1-C5E7-4B88-8F2B-282EF00599B2 Q37145188-B830A59C-F459-4A66-82C9-EECD1AC89FD6 Q37532636-4D1AEA28-955B-4003-9B6A-4B33A97A9BA8 Q38212607-28FAAE86-A188-4BDD-B073-744B3827DFD0 Q38522820-E8AFACAB-B2A3-40B5-AF52-BB2219A8A1BE Q45140936-DEB5EBFC-1CBE-4C71-9E96-681C461F1DC1 Q51361643-1E043856-BBF9-4E08-8E63-2C3782D27555

P2860

Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results

http://www.wikidata.org/entity/Q33397922

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase III randomized trial of ...... east cancer: long-term results

@ast

Phase III randomized trial of ...... east cancer: long-term results

@en

type

label

Phase III randomized trial of ...... east cancer: long-term results

@ast

Phase III randomized trial of ...... east cancer: long-term results

@en

prefLabel

Phase III randomized trial of ...... east cancer: long-term results

@ast

Phase III randomized trial of ...... east cancer: long-term results

@en

P1433

Q33397922-2E82425E-B418-4D12-92F3-3C9F208E681D

P1476

Q33397922-5916FCC5-A354-4158-8C52-023112669981

P2093

Q33397922-085A5995-FF6F-4579-A9A3-CBA35046A81B

Q33397922-199D6B66-05B3-4C66-A0C3-C6EF76BE973F

Q33397922-19E30CCA-19C4-45A9-8F55-3CB655B5E4DF

Q33397922-1C2DC9D1-0396-453F-A8B5-93DA4558D2CE

Q33397922-26E6609C-382D-4BF8-BE67-D4D480E62652

Q33397922-2FA73054-3380-4367-A4DD-29F07DA68C65

Q33397922-34185A98-B45D-48EE-ABB0-9A00A7C4D194

Q33397922-43DB30DF-BB40-4CCA-8F67-9DF678BA29D7

Q33397922-44EB0280-34A4-4E6E-86C9-B069AC69F6BE

Q33397922-5304C66D-FBDA-433F-8D61-173FC5892C36

P2860

Q33397922-0321A0F0-CFA2-4CF3-85B2-AFC84B54AB78

Q33397922-03D3BAC7-A5F2-4DFF-BB07-EC865B6351BC

Q33397922-09E862F9-4E16-4FA3-81CD-803D072BD358

Q33397922-10B36B9C-C23B-4D91-843D-A61950FA551A

Q33397922-18187C6C-1E86-4509-B68D-F4C69F1E808C

Q33397922-20BE2767-DD5E-4C04-8735-5845575910D5

Q33397922-347CEDCB-9718-4CC0-A526-A80FEDEFEF4C

Q33397922-5D0CEC41-114B-4DEE-9DFA-177B421ADC61

Q33397922-71D68E35-0403-4223-A786-214175CAA913

Q33397922-8638518E-FB95-49CA-A293-1FCF539F1350

P304

Q33397922-0321DF17-900D-48C4-BFCE-6B4C9382A82E

P31

Q33397922-AFA0595D-C8B5-455B-B220-2B9C0D136BB0

P356

Q33397922-E21147A4-6970-4E88-872D-7F4F6B1C20FB

P433

Q33397922-569D2495-F1B4-4C76-AF1D-22E67B1428B1

P478

Q33397922-E004A417-23CE-44EE-89A0-D2B9F1AD3A17

P577

Q33397922-BE05FE0E-F3F9-4FE0-927B-1EC7EC90AD5B

P5875

Q33397922-1174D556-F1BB-4CC4-A582-00DC40DD0F04

P698

Q33397922-9242CB58-1E25-4BD8-B190-CBF40246B9EB

P921

Q33397922-FBCF8DF2-8380-4993-B2B7-4F238B468E29

Q33397922-FC8D60A8-DDF9-445C-9609-4B2335889B36

P932

Q33397922-A55E9481-BBDD-4B75-ABE4-8B3D3B4A70A3

P356

THEONCOLOGIST.2011-0134

P1433

P1476

Phase III randomized trial of ...... east cancer: long-term results

@en

P2093

Aman U Buzdar

http://www.w3.org/2001/XMLSchema#string

Aysegul Sahin

http://www.w3.org/2001/XMLSchema#string

Banu K Arun

http://www.w3.org/2001/XMLSchema#string

Daniel Booser

http://www.w3.org/2001/XMLSchema#string

Debbie Frye

http://www.w3.org/2001/XMLSchema#string

Eric Strom

http://www.w3.org/2001/XMLSchema#string

Gabriel N Hortobagyi

http://www.w3.org/2001/XMLSchema#string

Guosheng Yin

http://www.w3.org/2001/XMLSchema#string

Kapil Dhinghra

http://www.w3.org/2001/XMLSchema#string

Kristine Broglio

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.

Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.

Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAK

Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience.

The importance of dose intensity in chemotherapy of metastatic breast cancer.

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.

Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.

P304

1527-1534

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2011-0134

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51760122

http://www.w3.org/2001/XMLSchema#string

P698

22042783

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

3233286

http://www.w3.org/2001/XMLSchema#string